表紙
市場調査レポート

B細胞性慢性リンパ性白血病:パイプライン分析

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 253678
出版日 ページ情報 英文 121 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
B細胞性慢性リンパ性白血病:パイプライン分析 B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016
出版日: 2016年02月29日 ページ情報: 英文 121 Pages
概要

B細胞性慢性リンパ性白血病は白血病の中で最も一般的な種類で、B細胞系のリンパ球に作用するものです。その病因は未だに不明ですが、血液細胞の増殖を制御する遺伝子に1〜2箇所の損傷が生じた結果だと思われています。また、家族歴も発症リスクを押し上げる要因となっています。その進行は遅いため、多くの人はその兆候に気づかず、定期的な血液検査で初めて発見されることが多いです。治療薬は錠剤または点滴の形で投与されます。

当レポートでは、世界各国でのB細胞性慢性リンパ性白血病(B-CLL)治療法のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 調査範囲

B細胞性慢性リンパ性白血病の概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • AB Science SA
  • Amgen Inc.
  • Celgene Corporation
  • Dynavax Technologies Corporation
  • エーザイ
  • Elsalys Biotech SAS
  • F. Hoffmann-La Roche Ltd.
  • iDD biotech SAS
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Molecular Templates Inc.
  • Noxxon Pharma AG
  • 小野薬品工業
  • Regeneron Pharmaceuticals, Inc.
  • TheraMAB LLC
  • Unum Therapeutics, Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 202-b
  • AB-8779
  • アレムツズマブのバイオシミラー
  • AMG-319
  • ATTCK-20
  • 悪性血液疾患向け細胞免疫療法
  • B細胞悪性腫瘍向け 4-1BBL活性および CD19標的細胞免疫療法
  • B細胞悪性腫瘍向け CD40L活性および CD19標的細胞免疫療法
  • B細胞悪性腫瘍向け IL-12活性および CD19 標的細胞免疫療法
  • B細胞非ホジキンリンパ腫・B細胞性慢性リンパ性白血病向け CD16標的細胞免疫療法
  • B細胞性慢性リンパ性白血病向け CD19標的細胞免疫療法
  • B細胞悪性腫瘍向け CD19標的細胞免疫療法
  • 腫瘍向け CD19標的細胞免疫療法
  • 腫瘍学向け CD19標的細胞免疫療法
  • E-7449
  • IDD-001
  • IDD-002
  • JNJ-64052781
  • lenalidomide
  • MAT-303
  • MT-3724
  • olaptesed pegol
  • ONO-4059
  • REGN-1979
  • SD-101
  • TAB-08
  • tocilizumab

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7660IDB

Summary

Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016', provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
  • The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects
  • The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • B-Cell Chronic Lymphocytic Leukemia Overview
  • Therapeutics Development
    • Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview
    • Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis
  • B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies
  • B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies
  • B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes
  • B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development
    • AB Science SA
    • Amgen Inc.
    • Celgene Corporation
    • Dynavax Technologies Corporation
    • Eisai Co., Ltd.
    • Elsalys Biotech SAS
    • F. Hoffmann-La Roche Ltd.
    • iDD biotech SAS
    • Immunomedics, Inc.
    • Johnson & Johnson
    • Juno Therapeutics Inc.
    • Molecular Templates Inc.
    • Noxxon Pharma AG
    • Ono Pharmaceutical Co., Ltd.
    • Regeneron Pharmaceuticals, Inc.
    • TheraMAB LLC
    • Unum Therapeutics, Inc.
  • B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 202-b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AB-8779 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alemtuzumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMG-319 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATTCK-20 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Hematological Malignancies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • E-7449 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDD-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDD-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-64052781 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAT-303 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MT-3724 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • olaptesed pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONO-4059 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REGN-1979 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SD-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAB-08 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects
  • B-Cell Chronic Lymphocytic Leukemia - Discontinued Products
  • B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement
      • Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2016
  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc., H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..1), H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..2), H1 2016
  • B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2016
  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top